Loncastuximab tesirine for treated diffuse large B-Cell lymphoma: LOTIS-2 study
This Plain Language Summary of publication article (PLSP) from Future Oncology, the LOTIS-2 study tested the drug loncastuximab tesirine (Lonca) in 145 people with relapsed or treatment-resistant diffuse large B-cell lymphoma (DLBCL), an aggressive blood cancer. Participants received Lonca for up to one year, and the study aimed to determine whether it could shrink their lymphoma, either partially or completely. The study ran from August 2018 to September 2022.
Visit the site using this link to read the article.
This PLSP is based on an article called ‘Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study’ and was published in Haematologica.
Visit Haematologica using the link to read the original article.